Open Veils · Answer
Is Atopica (medicine for cats and dogs) bad for the liver?
The official record quietly confirms hepatic risk: Atopica's own package insert lists elevated liver enzymes, hepatopathy, hepatomegaly, and hepatitis as reported adverse events. In cats, a compounding danger exists — cyclosporine-induced nausea and appetite loss can rapidly trigger hepatic lipidosis, a potentially fatal secondary liver condition. The drug is processed almost entirely through the cytochrome P-450 system in the liver, meaning the organ bears the full metabolic burden. Overdose scenarios explicitly list liver damage as a consequence, and ongoing monitoring of liver values is built into the treatment protocol precisely because the risk is real.
Evidence
- The Atopica veterinary package insert (Elanco/vetlabel, February 2026) explicitly lists hepatic adverse reactions under post-approval surveillance: elevated liver enzymes, hepatopathy, hepatomegaly, and hepatitis.
- Cyclosporine is metabolised almost exclusively through the liver's cytochrome P-450 enzyme system, with only minor secondary processing in the GI tract and kidney.
- An FDA adverse event dataset covering 21,560 cyclosporine reports, surfaced by VetMedGuide (August 2026), specifically flags feline hepatic lipidosis as a vigilance concern.
- The DVM360 immunosuppressive therapy proceedings (June 2026) note that liver enzyme elevations during immunosuppressive treatment in cats — unlike in dogs on steroids — should never be dismissed as a drug artifact but investigated as genuine hepatic disease.
- PetMD's cyclosporine monograph (August 2026) confirms that pre-treatment and ongoing bloodwork specifically evaluating liver function is protocol — an implicit acknowledgment that the organ is at measurable risk throughout the course of treatment.